The Cancer Letter

Inside information on cancer research and drug development

Clinical

Phase III Trial Confirms ORR in Previously Treated Patients who Received Opdivo

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Results from the CheckMate -275 trial, in which Opdivo confirmed objective response rate (ORR), the primary endpoint, of 19.6% (95% CI 15.0 – 24.9) in platinum-refractory patients with metastatic urothelial carcinoma, said Bristol-Myers Squibb, the drug’s sponsor.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

ACCC establishes bladder cancer care resource

The Association of Community Cancer Centers has established a new e-course, Implementing Shared Decision-Making in Bladder Cancer Care, as part of its resources for cancer care centers to access evidence-based health literacy principles and shared decision-making strategies to reduce disparities in bladder cancer care.
Clinical Roundup

SITC-IBCG publishes bladder cancer clinical trial design recommendations

The Society for Immunotherapy of Cancer and the International Bladder Cancer Group published bladder cancer clinical trial design recommendations, which provide a detailed clinical trial design guide to maximize the chance of capturing the benefit of medical therapies for each unique stage of bladder cancer, from low-risk non-muscle invasive bladder cancer to metastatic disease.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account